삼성서울병원

Ko En
의료진 검색
찾으실 의료진명을 입력하여 검색해주세요.

혈액종양내과 박준오 교수

진료분야
대장암, 담도암, 췌장암
진료일정 06 月
날짜
토
01
일
02
월
03
화
04
수
05
목
06
금
07
토
08
일
09
월
10
화
11
수
12
목
13
금
14
토
15
일
16
월
17
화
18
수
19
목
20
금
21
토
22
일
23
월
24
화
25
수
26
목
27
금
28
토
29
일
30
오전
오후
진료일정 07 月
날짜
월
01
화
02
수
03
목
04
금
05
토
06
일
07
월
08
화
09
수
10
목
11
금
12
토
13
일
14
월
15
화
16
수
17
목
18
금
19
토
20
일
21
월
22
화
23
수
24
목
25
금
26
토
27
일
28
월
29
화
30
수
31
오전
오후
본원외래 본원클리닉 본원육아상담 암병원외래 암병원클리닉 암병원육아상담

학력

학력
2001.02 연세대학교 대학원 의과학과 박사학위 취득
1995.02 연세대학교 대학원 의학과 석사학위 취득
1991.02 연세대학교 의과대학 졸업

경력

경력
2015.03 ~현재 삼성서울병원 암병원 특수암센터 센터장
2003.03 ~현재 성균관대학교 의과대학 의학과 교수
2002.03 ~현재 삼성서울병원 혈액종양내과 전문의
2006.02 ~ 2008.02 하버드의대 Dana-Farber Cancer Institute 연수
2001.03 ~ 2002.02 삼성서울병원 혈액종양내과 전임의
1999.03 ~ 2001.02 연세대학교 의과대학 내과학교실 및 연세 암센터 강사
1996.02 ~ 1999.04 공중보건의사
1992.03 ~ 1996.02 신촌 세브란스 병원 내과 전공의
1991.03 ~ 1992.02 신촌 세브란스 병원 인턴

학회활동

학회활동
미국암연구학회 (American Association Cancer Research) (1999현재)
미국임상종양학회 (American Society of Clinical Oncology) (1999현재)
대한암학회 (1995-현재)
유럽종양내과학회 (European Society of Medical Oncology) (2001-현재)
대한항암요법연구회 (1999-현재)
대한내과학회(1992-현재)
  • " alt="" />
  • " alt="" />

표적치료제에 대한 끊임없는 연구로 암환자와의 행복한 상생을 꿈꾸다. 혈액종양내과 박준오 교수

Oh Happy SMC 블로그
논문
  • Cancer Res Treat. 2017 Apr;49(2):350-357. doi: 10.4143/crt.2016.067. Epub 2016 Jul 19. Efficacy and Safety of Regorafenib in Korean Patients with Advanced Gastrointestinal Stromal Tumor after Failure of lmatinib and Sunitinib: A Multicenter Study Based on the Management Access Program Son MK11, Ryu MH1, Park JO2, Im SA3, Kim TY3, Lee SJ2, Ryoo BY1, Park SR1, Kang YK1.
    View PubMed
  • BMC Cancer. 2017 Mar 23;17(1):211. doi: 10.1186/s12885-017-3196-6. Prospective phase II trial of everolimus in PIK3CA amplification/mutation and/or PTEN loss patients with advanced solid tumors refractory to standard therapy Kim ST11, Lee J1, Park SH1, Park JO1, Park YS1, Kang WK1, Lim HY2.
    View PubMed
  • Ann Oncol. 2017 Mar 1;28(3):547-554. doi: 10.1093/annonc/mdw669. Rapamycin-insensitive companion of mTOR (RICTOR) amplification defines a subset of advanced gastric cancer and is sensitive to AZD2014-mediated mTORC1/2 inhibition Kim ST11, Kim SY1, Klempner SJ2,3, Yoon J4, Kim N4, Ahn S4,5, Bang H5,6, Kim KM5,6, Park W4, Park SH1, Park JO1, Park YS1, Lim HY1, Lee SH1, Park K1,6, Kang WK1, Lee J1.
    View PubMed
  • JAMA Oncol. 2016 Sep 22. doi: 10.1001/jamaoncol.2016.4115. Ramucirumab as Second-Line Treatment in Patients With Advanced Hepatocellular Carcinoma Analysis of REACH Trial Results by Child-Pugh Score Zhu AX11, Baron AD2, Malfertheiner P3, Kudo M4, Kawazoe S5, Pezet D6, Weissinger F7, Brandi G8, Barone CA9, Okusaka T10, Wada Y11, Park JO12, Ryoo BY13, Cho JY14, Chung HC15, Li CP16, Yen CJ17, Lee KD18, Chang SC19, Yang L20, Abada PB21, Chau I22.
    View PubMed
  • Oncotarget. 2017 Feb 14;8(7):11094-11104. doi: 10.18632/oncotarget.14362. Direct analysis of aberrant glycosylation on haptoglobin in patients with gastric cancer Kim JH11, Lee SH2, Choi S2, Kim U3, Yeo IS4, Kim SH2, Oh MJ3, Moon H3, Lee J3, Jeong S3, Choi MG5, Lee JH5, Sohn TS5, Bae JM5, Kim S5, Min YW5, Lee H5, Lee JH5, Rhee PL5, Kim JJ5, Lee SJ5, Kim ST5, Lee J5, Park SH5, Park JO5, Park YS5, Lim HY5, Kang WK5, An HJ3, Kim JH4.
    View PubMed
  • Oncotarget. 2017 Jan 10;8(2):3237-3245. doi: 10.18632/oncotarget.13700. The implication of FLT3 amplification for FLT targeted therapeutics in solid tumors Lim SH11, Kim SY1, Kim K2, Jang H1, Ahn S2, Kim KM2, Kim NK3, Park W3, Lee SJ1, Kim ST1, Park SH1, Park JO1, Park YS1, Lee SH1, Lim HY1, Park K1, Kang WK1, Lee J1.
    View PubMed
  • Mol Cancer Ther. 2017 Jan;16(1):228-238. doi: 10.1158/1535-7163.MCT-15-0887. Epub 2016 Nov 3. HER2 Status in Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma for Entry to the TRIO-O13/LOGiC Trial of Lapatinib Press MF11, Ellis CE2, Gagnon RC3, Grob TJ4, Buyse M5, Villalobos I6, Liang Z7, Wu S7, Bang YJ8, Qin SK9, Chung HC10, Xu J11, Park JO12, Jeziorski K13, Afenjar K14, Ma Y6, Estrada MC6, Robinson DM15, Scherer SJ15, Sauter G4, Hecht JR16, Slamon DJ16.
    View PubMed
  • Oncotarget. 2016 Nov 15;7(46):75482-75491. doi: 10.18632/oncotarget.12780. Second-line ramucirumab therapy for advanced hepatocellular carcinoma (REACH): an East Asian and non-East Asian subgroup analysis Park JO11, Ryoo BY2, Yen CJ3, Kudo M4, Yang L5, Abada PB6, Cheng R7, Orlando M8, Zhu AX9, Okusaka T10.
    View PubMed
  • Br J Cancer. 2016 Nov 8;115(10):1206-1214. doi: 10.1038/bjc.2016.309. Epub 2016 Oct 13. A phase 3 trial evaluating panitumumab plus best supportive care vs best supportive care in chemorefractory wild-type KRAS or RAS metastatic colorectal cancer Kim TW11, Elme A2, Kusic Z3, Park JO4, Udrea AA5, Kim SY6, Ahn JB7, Valencia RV8, Krishnan S9, Bilic A10, Manojlovic N11, Dong J12, Guan X12, Lofton-Day C12, Jung AS12, Vrdoljak E13.
    View PubMed
  • CANCER RESEARCH AND TREATMENT, OCT 2016, 48(4) :1274-1285, DOI: 10.4143/crt.2015.502 Is There a Role for Adjuvant Therapy in RO Resected Gallbladder Cancer?: A Propensity Score-Matched Analysis Go SI1, Kim YS, Hwang IG, Kim EY, Oh SY, Ji JH, Song HN, Park SH, Park JO, Kang JH
    View PubMed
  • J Cancer. 2016 Oct 25;7(15):2173-2178. eCollection 2016. To Excavate Biomarkers Predictive of the Response for Capecitabine plus RAD001 through Nanostring-Based Multigene Assay in Advanced Gastric Cancer Patients Lee H11, Lee J2, Sohn I3, Park SH2, Park JO2, Park YS2, Kim KM4, Kang WK2, Kim ST2.
    View PubMed
  • Oncotarget. 2016 Sep 20;7(38):62676-62686. doi: 10.18632/oncotarget.10445. Prognostic significance of survivin in rectal cancer patients treated with surgery and postoperative concurrent chemo-radiation therapy Yu JI11, Lee H2, Park HC1, Choi DH1, Choi YL3, Do IG4, Kim HC5, Lee WY5, Yun SH5, Cho YB5, Huh JW5, Park YA6, Park YS6, Park JO6, Kim ST6, Park W1.
    View PubMed
  • EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, JUL 2016, 43(8):1461-1468, DOI: 10.1007/s00259-016-3316-6 Intratumoral heterogeneity of F-18-FDG uptake predicts survival in patients with pancreatic ductal adenocarcinoma Hyun SH1, Kim HS, Choi SH, Choi DW, Lee JK, Lee KH, Park JO, Lee KH, Kim BT, Choi JY
    View PubMed
  • Oncotarget. 2016 Jul 12;7(28):43492-43503. doi: 10.18632/oncotarget.9523. MCT4 as a potential therapeutic target for metastatic gastric cancer with peritoneal carcinomatosis Lee JY11, Lee I2, Chang WJ3, Ahn SM4,5, Lim SH1, Kim HS1, Yoo KH1, Jung KS1, Song HN1, Cho JH1, Kim SY1, Kim KM4,5, Lee S1, Kim ST1, Park SH1, Lee J1, Park JO1, Park YS1, Lim HY1, Kang WK1.
    View PubMed
  • J Cancer Res Clin Oncol. 2016 Jun;142(6):1231-7. doi: 10.1007/s00432-016-2143-2. Epub 2016 Mar 16. Value of FGFR2 expression for advanced gastric cancer patients receiving pazopanib plus CapeOX (capecitabine and oxaliplatin) Kim ST11, Ahn S2, Lee J1, Lee SJ1, Park SH1, Park YS1, Lim HY1, Kang WK1, Kim KM2, Park JO3.
    View PubMed
  • Transl Oncol. 2016 Jun;9(3):173-8. doi: 10.1016/j.tranon.2016.01.007. Epub 2016 Apr 22. Genomic Alterations in Biliary Tract Cancer Using Targeted Sequencing Yoo KH11, Kim NK2, Kwon WI3, Lee C2, Kim SY1, Jang J1, Ahn J1, Kang M1, Jang H1, Kim ST1, Ahn S4, Jang KT4, Park YS1, Park WY5, Lee J6, Heo JS7, Park JO8.
    View PubMed
  • Cancer Chemother Pharmacol. 2016 May;77(5):979-85. doi: 10.1007/s00280-016-3014-x. Epub 2016 Mar 26. Role of adjuvant therapy after R0 resection for patients with distal cholangiocarcinoma Kim YS11, Hwang IG2, Park SE3, Go SI4, Kang JH4, Park I1, Oh SY5, Ji JH6, Song HN7, Park SH7, Kim ST7, Park JO7.
    View PubMed
  • J Cancer. 2016 May 25;7(9):1044-8. doi: 10.7150/jca.14815. eCollection 2016. Genomic Profiling of Metastatic Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients in the Personalized-Medicine Era Kim ST11, Lee SJ1, Park SH1, Park JO1, Lim HY1, Kang WK1, Lee J1, Park YS1.
    View PubMed
  • Oncotarget. 2016 Apr 12;7(15):19610-9. doi: 10.18632/oncotarget.7526. Molecular characterization of colorectal cancer patients and concomitant patient-derived tumor cell establishment Song HN11,2, Lee C3,4, Kim ST1, Kim SY1, Kim NK3, Jang J1, Kang M1, Jang H1, Ahn S5, Kim SH5, Park Y6, Cho YB6, Heo JW6, Lee WY6, Park JO1, Lim HY1, Kang WK1, Park YS1, Park WY3,7,4, Lee J1, Kim HC6.
    View PubMed
  • Cancer Res Treat. 2016 Apr;48(2):553-60. doi: 10.4143/crt.2015.155. Epub 2015 Aug 10. A Retrospective Analysis for Patients with HER2-Positive Gastric Cancer Who Were Treated with Trastuzumab-Based Chemotherapy: In the Perspectives of Ethnicity and Histology Yi JH11, Kang JH2, Hwang IG3, Ahn HK4, Baek HJ5, Lee SI5, Lim DH5, Won YW6, Ji JH7, Kim HS8, Rha SY8, Oh SY9, Lee KE10, Lim T11, Maeng CH12, Kim MJ13, Kim ST13, Lee J13, Park JO13, Park YS13, Lim HY13, Kang WK13, Park SH13.
    View PubMed
  • Oncotarget. 2016 Apr 26;7(17):24088-96. doi: 10.18632/oncotarget.8175. Prospective phase II trial of pazopanib plus CapeOX (capecitabine and oxaliplatin) in previously untreated patients with advanced gastric cancer Kim ST11, Lee J1, Lee SJ1, Park SH1, Jung SH2, Park YS1, Lim HY1, Kang WK1, Park JO1.
    View PubMed
  • Oncotarget. 2016 Mar 22;7(12):13797-809. doi: 10.18632/oncotarget.7318. Integrated genomic approaches identify upregulation of SCRN1 as a novel mechanism associated with acquired resistance to erlotinib in PC9 cells harboring oncogenic EGFR mutation Kim N11,2, Cho A2, Watanabe H3,4, Choi YL2,5, Aziz M6, Kassner M6, Joung JG7, Park AK1,2, Francis JM8, Bae JS7, Ahn SM5, Kim KM5, Park JO9, Park WY2,7, Ahn MJ9, Park K9, Koo J10, Yin HH6, Cho J1,2,7.
    View PubMed
  • J Clin Oncol. 2016 Feb 10;34(5):443-51. doi: 10.1200/JCO.2015.62.6598. Epub 2015 Nov 30. Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC-A Randomized Phase III Trial Hecht JR11, Bang YJ2, Qin SK2, Chung HC2, Xu JM2, Park JO2, Jeziorski K2, Shparyk Y2, Hoff PM2, Sobrero A2, Salman P2, Li J2, Protsenko SA2, Wainberg ZA2, Buyse M2, Afenjar K2, Houe V2, Garcia A2, Kaneko T2, Huang Y2, Khan-Wasti S2, Santillana S2, Press MF2, Slamon D2.
    View PubMed
  • Oncotarget. 2016 Feb 9;7(6):6538-51. doi: 10.18632/oncotarget.3731. Integrated genomic analyses identify frequent gene fusion events and VHL inactivation in gastrointestinal stromal tumors Kang G11,2, Yun H1,3, Sun CH3, Park I3, Lee S3, Kwon J3, Do I1,4,5, Hong ME1,5,6, Van Vrancken M1, Lee J7, Park JO7, Cho J8, Kim KM1,5, Sohn TS9.
    View PubMed
  • J Cancer. 2016 Feb 5;7(5):484-9. doi: 10.7150/jca.13711. eCollection 2016. The Impact of PD-L1 Expression in Patients with Metastatic GEP-NETs Kim ST11, Ha SY2, Lee S1, Ahn S2, Lee J1, Park SH1, Park JO1, Lim HY1, Kang WK1, Kim KM2, Park YS1.
    View PubMed
  • BMC Cancer. 2016 Feb 18;16:120. doi: 10.1186/s12885-016-2141-4. The impact of KRAS mutations on prognosis in surgically resected colorectal cancer patients with liver and lung metastases: a retrospective analysis Kim HS11,2, Heo JS3, Lee J4, Lee JY5, Lee MY6, Lim SH7, Lee WY8, Kim SH9, Park YA10, Cho YB11, Yun SH12, Kim ST13, Park JO14, Lim HY15, Choi YS16, Kwon WI17, Kim HC18, Park YS19.
    View PubMed
  • Medicine (Baltimore). 2016 Jan;95(3):e2582. doi: 10.1097/MD.0000000000002582. Mismatch Repair Gene Expression as a Predictor of Tumor Responses in Patients With Rectal Cancer Treated With Preoperative Chemoradiation Huh JW11, Kim HC, Kim SH, Park YA, Cho YB, Yun SH, Lee WY, Park HC, Choi DH, Park JO, Park YS, Chun HK.
    View PubMed
  • Cancer Res Treat. 2016 Jan;48(1):153-61. doi: 10.4143/crt.2014.183. Epub 2015 Mar 7. The Role of Plasma Chromogranin A as Assessment of Treatment Response in Non-functioning Gastroenteropancreatic Neuroendocrine Tumors Kim M11, Lee S2, Lee J2, Park SH2, Park JO2, Park YS2, Kang WK2, Kim ST2.
    View PubMed
  • Tumori. 2016 Jan-Feb;102(1):114-21. doi: 10.5301/tj.5000439. Epub 2015 Oct 7. Clinical significance of mucinous rectal adenocarcinoma following preoperative chemoradiotherapy and curative surgery Kim TG11, Park W2, Choi DH2, Park HC2, Kim SH3, Cho YB4, Yun SH4, Kim HC4, Lee WY4, Lee J5, Park JO5, Park YS5, Lim HY5, Kang WK5, Chun HK6.
    View PubMed
  • Oncotarget. 2015 Nov 24;6(37):40360-9. doi: 10.18632/oncotarget.5465. Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients Kim ST11, Lee WS2, Lanman RB3, Mortimer S3, Zill OA3, Kim KM4,5, Jang KT5, Kim SH5, Park SH1, Park JO1,4, Park YS1, Lim HY1, Eltoukhy H3, Kang WK1, Lee WY6, Kim HC6, Park K1,4, Lee J1,4, Talasaz A3.
    View PubMed
  • Oncotarget. 2015 Nov 24;6(37):40026-35. doi: 10.18632/oncotarget.5432. PIK3CA mutation detection in metastatic biliary cancer using cell-free DNA Kim ST11, Lira M2, Deng S2, Lee S1, Park YS1, Lim HY1, Kang WK1, Mao M3, Heo JS4, Kwon W4, Jang KT5, Lee J1,6, Park JO1,6.
    View PubMed
  • Oncotarget. 2015 Nov 17;6(36):39028-35. doi: 10.18632/oncotarget.5494. NTRK1 rearrangement in colorectal cancer patients: evidence for actionable target using patient-derived tumor cell line Lee SJ11, Li GG2, Kim ST1, Hong ME3, Jang J1, Yoon N3, Ahn SM3, Murphy D2, Christiansen J2, Wei G2, Hornby Z2, Lee DW4, Park JO1,5, Park YS1, Lim HY1, Hong SN6, Kim SH3, Kang WK1, Park K1, Park WY7, Kim KM3,5, Lee J1.
    View PubMed
  • Br J Cancer. 2015 Nov 17;113(10):1421-6. doi: 10.1038/bjc.2015.371. Epub 2015 Oct 27. A randomised, double-blind, placebo-controlled multi-centre phase III trial of XELIRI/FOLFIRI plus simvastatin for patients with metastatic colorectal cancer Lim SH11, Kim TW2, Hong YS2, Han SW3, Lee KH3, Kang HJ4, Hwang IG5, Lee JY1, Kim HS1, Kim ST1, Lee J1, Park JO1, Park SH1, Park YS1, Lim HY1, Jung SH6,7, Kang WK1.
    View PubMed
  • J Clin Oncol. 2015 Nov 20;33(33):3858-65. doi: 10.1200/JCO.2014.60.0320. Epub 2015 Aug 17. Randomized, Double-Blind Phase II Trial With Prospective Classification by ATM Protein Level to Evaluate the Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer Bang YJ11, Im SA2, Lee KW2, Cho JY2, Song EK2, Lee KH2, Kim YH2, Park JO2, Chun HG2, Zang DY2, Fielding A2, Rowbottom J2, Hodgson D2, O'Connor MJ2, Yin X2, Kim WH2.
    View PubMed
  • Radiother Oncol. 2015 Oct;117(1):171-7. doi: 10.1016/j.radonc.2015.08.009. Epub 2015 Aug 20. Effects of adjuvant radiotherapy on completely resected gastric cancer: A radiation oncologist's view of the ARTIST randomized phase III trial Yu JI11, Lim do H2, Ahn YC1, Lee J3, Kang WK3, Park SH3, Park JO3, Park YS3, Lim HY3, Kim ST3, Kim S4, Sohn TS4, Choi MG4, Bae JM4, Nam H5.
    View PubMed
  • BMC Cancer. 2015 Oct 20;15:747. doi: 10.1186/s12885-015-1759-y. Exploratory biomarker analysis for treatment response in KRAS wild type metastatic colorectal cancer patients who received cetuximab plus irinotecan Kim ST1, Ahn TJ, Lee E, Do IG, Lee SJ, Park SH, Park JO, Park YS, Lim HY, Kang WK, Kim SH, Lee J, Kim HC
    View PubMed
  • J Clin Oncol. 2015 Oct 1;33(28):3130-6. doi: 10.1200/JCO.2014.58.3930. Epub 2015 Jan 5. Phase III Trial to Compare Adjuvant Chemotherapy With Capecitabine and Cisplatin Versus Concurrent Chemoradiotherapy in Gastric Cancer: Final Report of the Adjuvant Chemoradiotherapy in Stomach Tumors Trial, Including Survival and Subset Analyses Park SH11, Sohn TS1, Lee J1, Lim DH1, Hong ME1, Kim KM1, Sohn I1, Jung SH1, Choi MG1, Lee JH1, Bae JM1, Kim S1, Kim ST1, Park JO1, Park YS1, Lim HY1, Kang WK2.
    View PubMed
  • Int J Biol Markers. 2015 Nov 11;30(4):e382-6. doi: 10.5301/jbm.5000151. Circulating tumor cells are predictive of poor response to chemotherapy in metastatic gastric cancer Lee SJ11, Lee J1, Kim ST1, Park SH1, Park JO1, Park YS1, Lim HY1, Kang WK1.
    View PubMed
  • Oncotarget. 2015 Oct 20;6(32):33358-68. doi: 10.18632/oncotarget.5188. The NEXT-1 (Next generation pErsonalized tX with mulTi-omics and preclinical model) trial: prospective molecular screening trial of metastatic solid cancer patients, a feasibility analysis Kim ST11, Lee J1, Hong M2,3, Park K4,5, Park JO1, Ahn T3,4, Park SH1, Park YS1, Lim HY1, Sun JM1, Ahn JS1, Ahn MJ1, Kim HC6, Sohn TS6, Choi DI7, Cho JH8, Heo JS6, Kwon W6, Uhm SW9, Lee H10, Min BH10, Hong SN10, Kim DH5,11, Jung SH12, Park W4,5, Kim KM2,3, Kang WK1, Park K1,2.
    View PubMed
  • Oncotarget. 2015 Sep 15;6(27):24320-32. Detection of novel and potentially actionable anaplastic lymphoma kinase (ALK) rearrangement in colorectal adenocarcinoma by immunohistochemistry screening Lee J11, Kim HC2, Hong JY3, Wang K4, Kim SY1, Jang J1, Kim ST1, Park JO1, Lim HY1, Kang WK1, Park YS1, Lee J1, Lee WY2, Park YA2, Huh JW2, Yun SH2, Do IG5, Kim SH5, Balasubramanian S4, Stephens PJ4, Ross JS4,6, Li GG7, Hornby Z7, Ali SM4, Miller VA4, Kim KM5,8, Ou SH9.
    View PubMed
  • Oncotarget. 2015 Sep 29;6(29):28211-22. doi: 10.18632/oncotarget.4721. Gastrointestinal malignancies harbor actionable MET exon 14 deletions Lee J11,2, Ou SH3, Lee JM4, Kim HC5, Hong M6, Kim SY1, Jang J1, Ahn S6, Kang SY6, Lee S1, Kim ST1, Kim B4, Choi J4, Kim KA4, Lee J1, Park C1,6, Park SH1, Park JO1,2, Lim HY1, Kang WK1, Park K1,2, Park YS1, Kim KM2,6.
    View PubMed
  • Oncotarget. 2015 Sep 22;6(28):25619-30. doi: 10.18632/oncotarget.4627. Patient-derived cell models as preclinical tools for genome-directed targeted therapy Lee JY11, Kim SY1, Park C1, Kim NK2, Jang J1, Park K2, Yi JH3, Hong M4,5, Ahn T2, Rath O6, Schueler J6, Kim ST1, Do IG5, Lee S1, Park SH1, Ji YI7, Kim D7, Park JO1,4, Park YS1, Kang WK1, Kim KM4,5, Park WY2,7, Lim HY1, Lee J1,4.
    View PubMed
  • Mol Ther. 2015 Sep;23(9):1532-40. doi: 10.1038/mt.2015.109. Epub 2015 Jun 15. Phase 1b Trial of Biweekly Intravenous Pexa-Vec (JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus in Colorectal Cancer Park SH11, Breitbach CJ2, Lee J1, Park JO1, Lim HY1, Kang WK1, Moon A2,3, Mun JH4, Sommermann EM4, Maruri Avidal L4, Patt R5, Pelusio A2, Burke J2, Hwang TH4,6, Kirn D2, Park YS1.
    View PubMed
  • Transl Oncol. 2015 Aug;8(4):288-94. doi: 10.1016/j.tranon.2015.06.001. Clinical Significance of IGFBP-3 Methylation in Patients with Early Stage Gastric Cancer Kim ST11, Jang HL2, Lee J1, Park SH1, Park YS1, Lim HY1, Choi MG3, Bae JM3, Sohn TS3, Noh JH3, Kim S3, Kim KM4, Kang WK1, Park JO5.
    View PubMed
  • BMC Cancer. 2015 Jul 21;15:530. doi: 10.1186/s12885-015-1552-y. Tumour shrinkage at 6 weeks predicts favorable clinical outcomes in a phase III study of gemcitabine and oxaliplatin with or without erlotinib for advanced biliary tract cancer Kim ST11, Jang KT2, Lee SJ3, Jang HL4, Lee J5, Park SH6, Park YS7, Lim HY8, Kang WK9, Park JO10.
    View PubMed
  • Cancer Res Treat. 2015 Jul;47(3):343-61. doi: 10.4143/crt.2014.308. Epub 2015 May 18. Gemcitabine Plus Cisplatin for Advanced Biliary Tract Cancer: A Systematic Review Park JO11, Oh DY2, Hsu C3, Chen JS4, Chen LT5, Orlando M6, Kim JS7, Lim HY1.
    View PubMed
  • Lancet Oncol. 2015 Jul;16(7):859-70. doi: 10.1016/S1470-2045(15)00050-9. Epub 2015 Jun 18. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial Zhu AX1, Park JO, Ryoo BY, Yen CJ, Poon R, Pastorelli D, Blanc JF, Chung HC, Baron AD, Pfiffer TE, Okusaka T, Kubackova K, Trojan J, Sastre J, Chau I, Chang SC, Abada PB, Yang L, Schwartz JD, Kudo M; REACH Trial Investigators.
    View PubMed
  • Oncology. 2015;89(1):14-22. doi: 10.1159/000371390. Epub 2015 Mar 11. Is Chemoradiotherapy Beneficial for Stage IV Rectal Cancer Huh JW11, Kim HC, Park HC, Choi DH, Park JO, Park YS, Park YA, Cho YB, Yun SH, Lee WY, Chun HK.
    View PubMed
  • Oncotarget. 2015 Apr 20;6(11):8839-50. Constitutive asymmetric dimerization drives oncogenic activation of epidermal growth factor receptor carboxyl-terminal deletion mutants Park AK11,2, Francis JM3, Park WY1,2, Park JO4, Cho J1,2.
    View PubMed
  • Cancer Chemother Pharmacol. 2015 Apr;75(4):757-62. doi: 10.1007/s00280-015-2691-1. Epub 2015 Feb 13. Phase II study of mFOLFOX3 (5-fluorouracil, leucovorin, oxaliplatin) as second-line treatment after gemcitabine failure in patients with unresectable/metastatic biliary tract cancer Hwang IG11, Jang JS, Oh SY, Rho MH, Lee S, Park YS, Park JO, Nam EM, Lee HR, Jun HJ, Chi KC.
    View PubMed
  • Int J Cancer. 2015 Apr 1;136(7):1629-35. doi: 10.1002/ijc.29159. Epub 2014 Sep 4. HER2-positive gastric cancer with concomitant MET and/or EGFR overexpression: A distinct subset of patients for dual inhibition therapy Ha SY11, Lee J, Jang J, Hong JY, Do IG, Park SH, Park JO, Choi MG, Sohn TS, Bae JM, Kim S, Kim M, Kim S, Park CK, Kang WK, Kim KM.
    View PubMed
  • Ann Surg Oncol. 2015 Apr;22(4):1308-14. doi: 10.1245/s10434-014-4146-z. Epub 2014 Oct 16. Salvage Radiation Therapy for Isolated Local Recurrence of Extrahepatic Cholangiocarcinoma After Radical Surgery: A Retrospective Study Kim SW11, Lim do H, Park HC, Park W, Park JO, Park YS.
    View PubMed
  • J Surg Oncol. 2015 Mar 15;111(4):439-44. doi: 10.1002/jso.23835. Epub 2014 Dec 9. Adjuvant Chemotherapy After Neoadjuvant Chemoradiation and Curative Resection for Rectal Cancer: Is it Necessary for all Patients Jung KU11, Kim HC, Park JO, Park YS, Park HC, Choi DH, Cho YB, Yun SH, Lee WY, Chun HK.
    View PubMed
  • Jpn J Clin Oncol. 2015 Mar;45(3):256-60. doi: 10.1093/jjco/hyu210. Epub 2015 Jan 26. Natural history of metastatic biliary tract cancer (BTC) patients with good performance status (PS) who were treated with only best supportive care (BSC) Ji JH11, Song HN2, Kim RB3, Oh SY4, Lim HY5, Park JO5, Park SH5, Kim MJ5, Lee SI6, Ryou SH6, Hwang IG7, Jang JS7, Kim HJ8, Choi JY9, Kang JH10.
    View PubMed
  • Transl Oncol. 2015 Feb;8(1):40-6. doi: 10.1016/j.tranon.2014.12.003. Molecular Subgroup Analysis of Clinical Outcomes in a Phase 3 Study of Gemcitabine and Oxaliplatin with or without Erlotinib in Advanced Biliary Tract Cancer Kim ST11, Jang KT2, Lee J1, Jang HM3, Choi HJ4, Jang HL1, Park SH1, Park YS1, Lim HY1, Kang WK1, Park JO5.
    View PubMed
  • Yonsei Med J. 2015 Jan;56(1):82-8. doi: 10.3349/ymj.2015.56.1.82. Immunohistochemical Detection of p53 Expression in Patients with Preoperative Chemoradiation for Rectal Cancer: Association with Prognosis Huh JW11, Lee WY2, Kim SH3, Park YA1, Cho YB1, Yun SH1, Kim HC1, Park HC4, Choi DH4, Park JO5, Park YS5, Chun HK6.
    View PubMed
  • Cancer Res Treat. 2015 Jan;47(1):72-7. doi: 10.4143/crt.2013.172. Epub 2014 Aug 21. Changes in the Mean Corpuscular Volume after Capecitabine Treatment are Associated with Clinical Response and Survival in Patients with Advanced Gastric Cancer Jung HA11, Kim HJ2, Maeng CH3, Park SH1, Lee J1, Park JO1, Park YS1, Lim HY1, Kang WK1.
    View PubMed
  • Sci Rep. 2014 Dec 23;4:7592. doi: 10.1038/srep07592. Anti-tumor efficacy of fulvestrant in estrogen receptor positive gastric cancer Yi JH11, Do IG2, Jang J3, Kim ST3, Kim KM4, Park SH3, Park JO3, Park YS3, Lim HY3, Kang WK3, Lee J3.
    View PubMed
  • Mol Cancer Ther. 2014 Nov;13(11):2527-36. doi: 10.1158/1535-7163.MCT-14-0255. Epub 2014 Sep 23. Pazopanib, a Novel Multitargeted Kinase Inhibitor, Shows Potent In Vitro Antitumor Activity in Gastric Cancer Cell Lines with FGFR2 Amplification Kim ST11, Jang HL2, Lee SJ1, Lee J1, Choi YL3, Kim KM3, Cho J4, Park SH1, Park YS1, Lim HY1, Yashiro M5, Kang WK1, Park JO6.
    View PubMed
  • Anticancer Res. 2014 Nov;34(11):6585-91. Adjuvant Chemoradiation with 5-Fluorouracil/Leucovorin versus S-1 in Gastric Cancer Patients Following D2 Lymph Node Dissection Surgery: A Feasibility Study Lee SJ11, Sohn TS2, Lee J1, Park SH1, Park JO1, Lim DH3, Park YS1, Lim HY1, Choi MG4, Lee JH4, Bae JM4, Kim S4, Kang WK5.
    View PubMed
  • Nat Commun. 2014 Nov 19;5:5477. doi: 10.1038/ncomms6477. Genomic landscape and genetic heterogeneity in gastric adenocarcinoma revealed by whole-genome sequencing Wong SS11, Kim KM2, Ting JC1, Yu K1, Fu J3, Liu S4, Cristescu R5, Nebozhyn M5, Gong L4, Yue YG1, Wang J1, Ronghua C5, Loboda A5, Hardwick J5, Liu X5, Dai H5, Jin JG3, Ye XS1, Kang SY2, Do IG2, Park JO6, Sohn TS7, Reinhard C1, Lee J6, Kim S7, Aggarwal A1.
    View PubMed
  • Eur J Cancer. 2014 Nov;50(16):2822-30. doi: 10.1016/j.ejca.2014.08.005. Epub 2014 Sep 15. Simvastatin plus capecitabine-cisplatin versus placebo plus capecitabine-cisplatin in patients with previously untreated advanced gastric cancer: A double-blind randomised phase 3 study Kim ST11, Kang JH2, Lee J1, Park SH1, Park JO1, Park YS1, Lim HY1, Hwang IG3, Lee SC4, Park KW5, Lee HR6, Kang WK7.
    View PubMed
  • Lancet Oncol. 2014 Oct;15(11):1245-53. doi: 10.1016/S1470-2045(14)70377-8. Epub 2014 Sep 4. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial Hong YS11, Nam BH2, Kim KP1, Kim JE1, Park SJ1, Park YS3, Park JO3, Kim SY4, Kim TY5, Kim JH6, Ahn JB7, Lim SB8, Yu CS8, Kim JC8, Yun SH9, Kim JH10, Park JH10, Park HC11, Jung KH1, Kim TW12.
    View PubMed
  • Cancer Genomics Proteomics. 2014 Sep-Oct;11(5):259-66. Transcriptome Analysis of CD133-positive Stem Cells and Prognostic Value of Survivin in Colorectal Cancer Kim ST11, Sohn I2, DO IG3, Jang J4, Kim SH3, Jung IH5, Park JO1, Park YS1, Talasaz A6, Lee J1, Kim HC7.
    View PubMed
  • Colorectal Dis. 2014 Aug;16(8):O257-63. doi: 10.1111/codi.12554. The adequacy of the distal resection margin after preoperative chemoradiotherapy for rectal cancer Kim TG11, Park W, Choi DH, Kim SH, Kim HC, Lee WY, Park JO, Park YS.
    View PubMed
  • PLoS One. 2014 Aug 4;9(8):e103551. doi: 10.1371/journal.pone.0103551. eCollection 2014. Activated cMET and IGF1R-Driven PI3K Signaling Predicts Poor Survival in Colorectal Cancers Independent of KRAS Mutational Status Lee J11, Jain A2, Kim P2, Lee T2, Kuller A2, Princen F2, In-GuDo3, Kim SH3, Park JO1, Park YS1, Singh S2, Kim HC4.
    View PubMed
  • Eur J Cancer. 2014 Aug;50(12):2072-81. doi: 10.1016/j.ejca.2014.04.024. Epub 2014 Jun 7. A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas Infante JR11, Somer BG2, Park JO3, Li CP4, Scheulen ME5, Kasubhai SM6, Oh DY7, Liu Y8, Redhu S8, Steplewski K8, Le N9.
    View PubMed
  • Med Oncol. 2014 Jul;31(7):23. doi: 10.1007/s12032-014-0023-7. Epub 2014 Jun 10. Prognostic and predictive value of metabolic tumor volume on F-18-FDG PET/CT in advanced biliary tract cancer treated with gemcitabine/oxaliplatin with or without erlotinib Choi MK111, Choi JY, Lee J, Heo JS, Choi SH, Choi DW, Lee KT, Lee JK, Lee KH, Park JO, Park YS, Lim HY.
    View PubMed
  • Invest New Drugs. 2014 Jun;32(3):535-41. doi: 10.1007/s10637-014-0065-x. Epub 2014 Jan 28. Effect of simvastatin plus cetuximab/irinotecan for KRAS mutant colorectal cancer and predictive value of the RAS signature for treatment response to cetuximab Lee J11, Hong YS, Hong JY, Han SW, Kim TW, Kang HJ, Kim TY, Kim KP, Kim SH, Do IG, Kim KM, Sohn I, Park SH, Park JO, Lim HY, Cho YB, Lee WY, Yun SH, Kim HC, Park YS, Kang WK.
    View PubMed
  • Ann Surg Oncol. 2014 Apr;21(4):1099-106. doi: 10.1245/s10434-013-3339-1. Epub 2013 Dec 4. CD151 Overexpression is Associated with Poor Prognosis in Patients with pT3 Gastric Cancer Ha SY11, Do IG, Lee J, Park SH, Park JO, Kang WK, Choi MG, Lee JH, Bae JM, Kim S, Kim KM, Sohn TS.
    View PubMed
  • PLoS One. 2014 Mar 5;9(3):e90133. doi: 10.1371/journal.pone.0090133. eCollection 2014. Nanostring-Based Multigene Assay to Predict Recurrence for Gastric Cancer Patients after Surgery Lee J11, Sohn I2, Do IG3, Kim KM4, Park SH1, Park JO1, Park YS1, Lim HY1, Sohn TS5, Bae JM5, Choi MG5, Lim DH6, Min BH7, Lee JH7, Rhee PL7, Kim JJ7, Choi DI8, Tan IB9, Das K10, Tan P11, Jung SH2, Kang WK1, Kim S5.
    View PubMed
  • Int J Colorectal Dis. 2014 Feb;29(2):193-200. doi: 10.1007/s00384-013-1797-3. Epub 2013 Dec 10. Factors associated with lateral pelvic recurrence after curative resection following neoadjuvant chemoradiotherapy in rectal cancer patients Kim TG11, Park W, Choi DH, Park HC, Kim SH, Cho YB, Yun SH, Kim HC, Lee WY, Lee J, Park JO, Park YS, Lim HY, Kang WK, Chun HK.
    View PubMed
  • Cancer Chemother Pharmacol. 2014 Jan;73(1):125-30. doi: 10.1007/s00280-013-2328-1. Epub 2013 Oct 27. Randomized double-blinded, placebo-controlled phase II trial of simvastatin and gemcitabine in advanced pancreatic cancer patients Hong JY11, Nam EM, Lee J, Park JO, Lee SC, Song SY, Choi SH, Heo JS, Park SH, Lim HY, Kang WK, Park YS.
    View PubMed
  • Lancet Oncol. 2013 May;14(6):490-9. doi: 10.1016/S1470-2045(13)70102-5. Epub 2013 Apr 15. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial Lordick F1, Kang YK, Chung HC, Salman P, Oh SC, Bodoky G, Kurteva G, Volovat C, Moiseyenko VM, Gorbunova V, Park JO, Sawaki A, Celik I, G?tte H, Melez?nkov? H, Moehler M; Arbeitsgemeinschaft Internistische Onkologie and EXPAND Investigators.
    View PubMed
  • Am J Clin Oncol.?2012 Oct;35(5):432-8. Safety and Efficacy of Adjuvant Chemoradiation Therapy With Capecitabine After Resection of Pancreatic Ductal Adenocarcinoma A Retrospective Review Kim ST11,?Lee J,?Park SH,?Lee JK,?Lee KT,?Lee KH,?Heo JS,?Choi SH,?Choi DW,?Park YS,?Lim HY,?Kang WK,?Jang KT,?Park HC,?Lim do H,?Park JO.
    View PubMed
  • Pharmacogenomics. 2012 Jul;13(9):1023-35. doi: 10.2217/pgs.12.82. Effect of genetic polymorphisms on therapeutic response and clinical outcomes in pancreatic cancer patients treated with gemcitabine Woo HI11, Kim KK, Choi H, Kim S, Jang KT, Yi JH, Park YS, Park JO, Lee SY.
    View PubMed
  • Nephrol Dial Transplant. 2012 Jan;27(1):218-25. doi: 10.1093/ndt/gfr267. Epub 2011 May 28. Uremia induces functional incompetence of bone marrow-derived stromal cells Noh H11, Yu MR, Kim HJ, Jeon JS, Kwon SH, Jin SY, Lee J, Jang J, Park JO, Ziyadeh F, Han DC, Lee HB.
    View PubMed
  • Mol?Cancer?Ther.?2011 Oct;10(10):1993-9. doi: 10.1158/1535-7163.MCT-11-0269. Epub 2011 Aug 23. Impact of KRAS Mutations on Clinical Outcomes in Pancreatic Cancer Patients Treated with First-line Gemcitabine-Based Chemotherapy Kim ST11,?Lim do H,?Jang KT,?Lim T,?Lee J,?Choi YL,?Jang HL,?Yi JH,?Baek KK,?Park SH,?Park YS,?Lim HY,?Kang WK,?Park JO.
    View PubMed
  • Oncology. 2011;80(3-4):175-80. doi: 10.1159/000328449. Epub 2011 Jun 24. A Prognostic Model to Predict Clinical Outcomes with First-Line Gemcitabine-Based Chemotherapy in Advanced Pancreatic Cancer Yi JH11, Lee J, Park SH, Lee KT, Lee JK, Lee KH, Choi DW, Choi SH, Heo JS, Lim do H, Park YS, Lim HY, Kang WK, Park K, Park JO.
    View PubMed
  • Oncology. 2011;80(3-4):257-61. doi: 10.1159/000328795. Epub 2011 Jul 6. High-Dose Ifosfamide as Second- or Third-Line Chemotherapy in Refractory Bone and Soft Tissue Sarcoma Patients Lee SH11, Chang MH, Baek KK, Han B, Lim T, Lee J, Park JO.
    View PubMed
  • Oncol Rep.?2011 Jun;25(6):1517-24. doi: 10.3892/or.2011.1219. Epub 2011 Mar 18. Impact of MET amplification on gastric cancer: Possible roles as a novel prognostic marker and a potential therapeutic target Lee J11,?Seo JW,?Jun HJ,?Ki CS,?Park SH,?Park YS,?Lim HY,?Choi MG,?Bae JM,?Sohn TS,?Noh JH,?Kim S,?Jang HL,?Kim JY,?Kim KM,?Kang WK,?Park JO.
    View PubMed
  • Oncol Rep. 2011 Jun;25(6):1517-24. doi: 10.3892/or.2011.1219. Epub 2011 Mar 18. Analysis of Prognostic Factors of Pediatric-Type Sarcomas in Adult Patients Lee J11, Seo JW, Jun HJ, Ki CS, Park SH, Park YS, Lim HY, Choi MG, Bae JM, Sohn TS, Noh JH, Kim S, Jang HL, Kim JY, Kim KM, Kang WK, Park JO.
    View PubMed
  • Eur J Clin Pharmacol. 2010 Dec;66(12):1235-45. doi: 10.1007/s00228-010-0885-3. Epub 2010 Sep 9. Population pharmacokinetics of CPT-11 (irinotecan) in gastric cancer patients with peritoneal seeding after its intraperitoneal administration Ahn BJ11, Choi MK, Park YS, Lee J, Park SH, Park JO, Lim HY, Kang WK, Ko JW, Yim DS.
    View PubMed
  • Anticancer Drugs. 2010 Jan;21(1):107-12. doi: 10.1097/CAD.0b013e328332a7fc. Definitive chemoradiation therapy with capecitabine in locally advanced pancreatic cancer Kim HS11, Yi SY, Jun HJ, Lee J, Park SH, Lee JK, Lee KT, Lee KH, Choi DW, Choi SH, Heo JS, Park YS, Lim HY, Kang WK, Park HC, Lim do H, Park JO.
    View PubMed
  • Cancer Lett. 2009 Sep 8;282(1):14-24. doi: 10.1016/j.canlet.2009.02.056. Epub 2009 Apr 3. Sensitivity of breast cancer cell lines to the novel insulin-like growth factor-1 receptor (IGF-1R) inhibitor NVP-AEW541 is dependent on the level of IRS-1 expression Mukohara T11, Shimada H, Ogasawara N, Wanikawa R, Shimomura M, Nakatsura T, Ishii G, Park JO, J?nne PA, Saijo N, Minami H.
    View PubMed
  • Oncology. 2009;76(5):326-32. doi: 10.1159/000209384. Epub 2009 Mar 23. A Prospective, Multicenter, Phase 2 Study of Imatinib Mesylate in Korean Patients with Metastatic or Unresectable Gastrointestinal Stromal Tumor Ryu MH11, Kang WK, Bang YJ, Lee KH, Shin DB, Ryoo BY, Roh JK, Kang JH, Lee H, Kim TW, Chang HM, Park JO, Park YS, Kim TY, Kim MK, Lee WK, Kang HJ, Kang YK.
    View PubMed
  • J Clin Oncol. 2007 Nov 20;25(33):5233-9. Phase III trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinum-based chemotherapy in non-small-cell lung cancer Park JO11, Kim SW, Ahn JS, Suh C, Lee JS, Jang JS, Cho EK, Yang SH, Choi JH, Heo DS, Park SY, Shin SW, Ahn MJ, Lee JS, Yun YH, Lee JW, Park K.
    View PubMed
  • Cancer Chemother Pharmacol. 2007 Sep;60(4):489-94. Epub 2007 Mar 30. A phase II trial of gemcitabine plus capecitabine for patients with advanced pancreatic adenocarcinoma Park BB11, Park JO, Lee HR, Lee J, Choi DW, Choi SH, Heo JS, Lee JK, Lee KT, Lim do H, Park YS, Lim HY, Kang WK, Park K.
    View PubMed
  • J Gastroenterol Hepatol. 2006 Jun;21(6):999-1003. Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplilications, and KRAS mutations on survival of pancreatic adenocarcinoma Park BK11, Kim YJ, Park JY, Bang S, Park SW, Chung JB, Kim KS, Choi JS, Lee WJ, Song SY.
    View PubMed
  • J Gastroenterol Hepatol. 2006 Jun;21(6):999-1003. A Phase II study of gemcitabine and cisplatin in advanced biliary tract cancer Park BK11, Kim YJ, Park JY, Bang S, Park SW, Chung JB, Kim KS, Choi JS, Lee WJ, Song SY.
    View PubMed
  • Cancer Chemother Pharmacol. 2006 Jan;57(1):91-6. Epub 2005 Nov 5. Anemia is the strongest prognostic factor for outcomes of 5-fluorouracil-based first-line chemotherapy in patients with advanced gastric cancer Park SH11, Lee J, Lee SH, Park JO, Kim K, Kim WS, Jung CW, Park YS, Kang WK, Park K, Kim S, Bang SM, Cho EK, Shin DB, Lee JH.
    View PubMed
  • Hepatocellular carcinoma with metastasis to the breast
  • Cancer Chemother Pharmacol.?2004 Nov;54(5):385-90. Epub 2004 Jul 10. Phase II study of doxorubicin and cisplatin in patients with metastatic hepatocellular carcinoma Lee J11,?Park JO,?Kim WS,?Park SH,?Park KW,?Choi MS,?Lee JH,?Koh KC,?Paik SW,?Yoo BC,?Joh J,?Kim K,?Jung CW,?Park YS,?Im YH,?Kang WK,?Lee MH,?Park K.
    View PubMed
  • Oncology.?2004;66(1):32-7. Phase II study of gemcitabine combined with uracil-tegafur in metastatic pancreatic cancer Lee J11,?Park JO,?Kim WS,?Lee SI,?Song SY,?Lim DH,?Choi SH,?Heo JS,?Lee KT,?Lee JK,?Kim K,?Jung CW,?Im YH,?Lee MH,?Kang WK,?Park K.
    View PubMed
  • Bone Marrow Transplant. 2003 Nov;32(9):889-95. Autologous peripheral blood stem cell transplantation with induction of autologous graft-versus-host disease in acute myeloid leukemia Park J11, Lee MH, Lee HR, Park SH, Lee SH, Lee KE, Lee H, Park JO, Kim K, Jung CW, Im YH, Kang WK, Ko YH, Park K.
    View PubMed
  • Jpn J Clin Oncol. 2003 Oct;33(10):533-7. Measuring response in solid tumors: Comparison of RECIST and WHO response criteria Park JO11, Lee SI, Song SY, Kim K, Kim WS, Jung CW, Park YS, Im YH, Kang WK, Lee MH, Lee KS, Park K.
    View PubMed